Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept

The purpose of this study was to determine whether the baseline metabolic profile (that is, metabotype) of a patient with major depressive disorder (MDD) would define how an individual will respond to treatment. Outpatients with MDD were randomly assigned to sertraline (up to 150 mg per day) (N=43)...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaddurah-Daouk, R, Boyle, S H, Matson, W, Sharma, S, Matson, S, Zhu, H, Bogdanov, M B, Churchill, E, Krishnan, R R, Rush, A J, Pickering, E, Delnomdedieu, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3232004/
https://www.ncbi.nlm.nih.gov/pubmed/22162828
http://dx.doi.org/10.1038/tp.2011.22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3232004/
https://www.ncbi.nlm.nih.gov/pubmed/22162828
http://dx.doi.org/10.1038/tp.2011.22

Ejemplares similares